Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. Eisenhauer EA, et al. Among authors: sargent d. Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. Eur J Cancer. 2009. PMID: 19097774
Reply to Verlingue, Koscielny and Ferté.
Litière S, De Vries EG, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST committee. Litière S, et al. Among authors: sargent d. Eur J Cancer. 2014 Nov;50(16):2889-91. doi: 10.1016/j.ejca.2014.08.001. Epub 2014 Sep 15. Eur J Cancer. 2014. PMID: 25219450 No abstract available.
Individual patient data analysis to assess modifications to the RECIST criteria.
Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P; RECIST Working Party. Bogaerts J, et al. Among authors: sargent d. Eur J Cancer. 2009 Jan;45(2):248-60. doi: 10.1016/j.ejca.2008.10.027. Epub 2008 Dec 16. Eur J Cancer. 2009. PMID: 19095437
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. Seymour L, et al. Among authors: sargent d. Clin Cancer Res. 2010 Mar 15;16(6):1764-9. doi: 10.1158/1078-0432.CCR-09-3287. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215557 Free PMC article.
Lessons learned from independent central review.
Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Ford R, et al. Among authors: sargent d. Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031. Eur J Cancer. 2009. PMID: 19101138
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. van Rooijen KL, et al. Among authors: sargent dj. Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30. Eur J Cancer. 2018. PMID: 29353165
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group. Sargent D, et al. Eur J Cancer. 2011 May;47(7):990-6. doi: 10.1016/j.ejca.2010.12.015. Epub 2011 Jan 21. Eur J Cancer. 2011. PMID: 21257306 Free PMC article.
540 results